Heska Co. (NASDAQ:HSKA – Get Rating) saw a large growth in short interest in August. As of August 31st, there was short interest totalling 691,500 shares, a growth of 12.4% from the August 15th total of 615,100 shares. Currently, 6.8% of the shares of the company are sold short. Based on an average daily trading volume, of 94,900 shares, the days-to-cover ratio is presently 7.3 days.
Institutional Trading of Heska
Hedge funds and other institutional investors have recently bought and sold shares of the company. Hardy Reed LLC bought a new stake in Heska during the 1st quarter worth approximately $115,000. Bares Capital Management Inc. increased its holdings in Heska by 55.8% during the 4th quarter. Bares Capital Management Inc. now owns 50,500 shares of the medical research company’s stock worth $9,216,000 after acquiring an additional 18,090 shares during the period. Grandeur Peak Global Advisors LLC increased its holdings in Heska by 2.9% during the 4th quarter. Grandeur Peak Global Advisors LLC now owns 148,343 shares of the medical research company’s stock worth $27,071,000 after acquiring an additional 4,249 shares during the period. Segall Bryant & Hamill LLC increased its holdings in shares of Heska by 41.8% in the 4th quarter. Segall Bryant & Hamill LLC now owns 56,896 shares of the medical research company’s stock worth $10,379,000 after buying an additional 16,760 shares during the last quarter. Finally, Teacher Retirement System of Texas increased its holdings in shares of Heska by 7.4% in the 1st quarter. Teacher Retirement System of Texas now owns 2,124 shares of the medical research company’s stock worth $294,000 after buying an additional 147 shares during the last quarter. Institutional investors own 97.39% of the company’s stock.
Wall Street Analysts Forecast Growth
Separately, Piper Sandler upped their price target on shares of Heska to $170.00 in a research note on Monday, August 22nd. Two analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to MarketBeat, Heska presently has a consensus rating of “Moderate Buy” and an average target price of $184.00.
Heska Stock Performance
Heska Company Profile
Heska Corporation sells veterinary and animal health diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Mexico, Australia, France, Germany, Italy, Malaysia, Spain, and Switzerland. The company offers Element DC, Element DCX, Element DC5x veterinary chemistry analyzers for blood chemistry and electrolyte analysis; Element RC, Element RCX, and Element RC3X chemistry systems for blood chemistry and electrolyte analysis; Element HT5 and scil Vet abc Plus veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; Element i immunodiagnostic analyzers; and Element COAG and Element AIM veterinary analyzers.
- Get a free copy of the StockNews.com research report on Heska (HSKA)
- 3 Airline Stocks Stuck in a Holding Pattern
- Roku Stock is Down but Not Out
- Is Ford Rolling To A Rebound After Its Q3 Warning
- If You’re Hungry for Value, Take a Bite on Ruth’s Hospitality Grp
- Has AMD stock stock fallen too far?
Receive News & Ratings for Heska Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska and related companies with MarketBeat.com's FREE daily email newsletter.